Finance

Beta
Lists
RCEL:NASDAQ
AVITA Medical Inc
$4.18
-4.13%
(-0.18) 1D
Jun 5, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RCEL...
Open
$4.32
High
$4.42
Low
$4.13
Mkt. cap
128.65M
Avg. vol.
250.65K
Volume
297.65K
52-wk high
$7.12
52-wk low
$3.22
EPS
-$1.57
Beta
1.87
Shares outstanding
30.78M
No. of employees
226
Open
$4.32
High
$4.42
Low
$4.13
Mkt. cap
128.65M
Avg. vol.
250.65K
Volume
297.65K
52-wk high
$7.12
52-wk low
$3.22
EPS
-$1.57
Beta
1.87
Shares outstanding
30.78M
No. of employees
226
Analyst outlook
Analyst Ratings
Based on 4 analysts giving stock ratings to RCEL in the past 3 months
Strong Buy
Buy
3
Hold
1
Sell
0
12 month forecast
Based on 4 Wall Street analysts offering 12 month price targets for RCEL in the last 3 months.
Highest
Current $4.18
$10.00 (+139.23%)
Average
$7.17 (+71.53%)
Lowest
$5.50 (+31.58%)
News stories
From sources across the web
Profile
Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East, Africa and Australia. Wikipedia
About AVITA Medical Inc
CEOJames Corbett
Employees226
Founded1999
HeadquartersValencia, California, United States
SectorBiotechnology
Websiteavitamedical.com
Previous reportsAll values in AUD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
18.42M
17.06M
17.62M
19.25M
Cost of goods sold
3.47M
3.19M
3.30M
3.52M
Cost of revenue
3.47M
3.19M
3.30M
3.52M
Research and development expenses
5.12M
3.75M
5.69M
5.63M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
20.98M
19.28M
19.03M
18.90M
Operating expense
26.10M
23.03M
24.72M
24.53M
Total operating expenses
29.57M
26.22M
28.02M
28.05M
Operating income
-11.15M
-9.15M
-10.41M
-8.80M
Other non operating income
3.38M
-2.15M
737.00K
-95.00K
EBT including unusual items
-9.92M
-13.17M
-11.64M
-10.62M
EBT excluding unusual items
-9.02M
-12.27M
-11.04M
-10.32M
Income tax expense
4.00K
15.00K
-17.00K
-11.00K
Effective tax rate
-0.04%
-0.11%
0.15%
0.10%
Other operating expenses
-
-
-
-
Net income
-9.92M
-13.19M
-11.62M
-10.61M
Net profit margin
-53.86%
-77.29%
-65.97%
-55.12%
Earnings per share
-
-
-
-
Interest and investment income
400.00
300.00K
200.00K
-
Interest expense
-1.25M
-1.27M
-1.55M
-1.42M
Net interest expenses
-1.25M
-970.20K
-1.35M
-1.42M
Depreciation and amortization charges
-
-
-
-
EBITDA
-10.60M
-8.58M
-9.76M
-8.18M
Gain or loss from assets sale
335.00K
252.00K
5.00K
55.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer